New hope for rare clotting disorder: drug safety trial launches
NCT ID NCT07584083
First seen May 15, 2026 · Last updated May 15, 2026
Summary
This study tests a drug called anifrolumab in 20 adults with antiphospholipid syndrome (APS), a condition that raises the risk of blood clots and pregnancy complications. Participants receive weekly injections for a year alongside their usual treatments. The main goal is to check if the drug is safe and tolerable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIPHOSPHOLIPID SYNDROME (APS) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.